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Optimization of large animal MI 
models; a systematic analysis of 
control groups from preclinical 
studies
P. P. Zwetsloot1, L. H. J. A. Kouwenberg1, E. S. Sena  2, J. E. Eding3, H. M. den Ruijter1, J. P. G. 
Sluijter1,4,5, G. Pasterkamp1,6, P. A. Doevendans1,4,5,6, I. E. Hoefer7, S. A. J. Chamuleau1,4,5, G. 
P. J. van Hout1 & S. J. Jansen of Lorkeers1
Large animal models are essential for the development of novel therapeutics for myocardial infarction. 
To optimize translation, we need to assess the effect of experimental design on disease outcome and 
model experimental design to resemble the clinical course of MI. The aim of this study is therefore to 
systematically investigate how experimental decisions affect outcome measurements in large animal 
MI models. We used control animal-data from two independent meta-analyses of large animal MI 
models. All variables of interest were pre-defined. We performed univariable and multivariable meta-
regression to analyze whether these variables influenced infarct size and ejection fraction. Our analyses 
incorporated 246 relevant studies. Multivariable meta-regression revealed that infarct size and cardiac 
function were influenced independently by choice of species, sex, co-medication, occlusion type, 
occluded vessel, quantification method, ischemia duration and follow-up duration. We provide strong 
systematic evidence that commonly used endpoints significantly depend on study design and biological 
variation. This makes direct comparison of different study-results difficult and calls for standardized 
models. Researchers should take this into account when designing large animal studies to most closely 
mimic the clinical course of MI and enable translational success.
Large animal studies are needed to test therapeutic efficacy of novel therapies for myocardial infarction (MI). 
These studies usually serve as crucial checkpoints before advancing to first-in-man trials1,2. Considerable heter-
ogeneity exists in the models currently used to study MI and its aftermath3. The choice for a specific model may 
influence the manifestation and progression of the disease and subsequently the potential effect of an intervention 
or technique under evaluation3.
There is a strong demand for optimal selection of models that represent the human disease best, since many 
promising therapeutics have shown beneficial effects in the preclinical phases, but fail in the clinical setting4. 
Methodological flaws and inadequate modeling of human MI have been proposed as partial explanations of 
this ‘translational failure’, leading to false positive study outcomes and the risk of overestimation of effect size in 
preclinical studies5–8. However, systematic analysis of methodological decisions on effect size are currently not 
available.
Standardization of these animal models could be of value for comparison of individual studies to historical 
data, for which groups in the field of cardioprotection have put forth the first efforts2,9. Above all, the translational 
value of large animal MI models can be significantly increased by assessing the effect of model design on primary 
outcome. This enables selection of animal models that most resemble the clinical course of MI.
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In the evolving era of big data and abundant publication, the research community is calling on meta-research 
to systematically evaluate and improve research methods10,11. Systematic reviews and meta-analyses of preclin-
ical data not only provide us with comprehensive overviews and bias assessments, but can also provide us with 
additional insights that explain heterogeneity within a specific disease and intervention12. In this perspective, 
combining and examining control groups of preclinical studies for a certain disease model, provides us with a 
comprehensive data-heavy method of studying the progression of the disease model and quantify the potential 
influence of certain variables on standard disease outcomes. The aim of the current study was to systematically 
explore the natural course of artificially induced MI in different large animal models and ultimately determine 
which biological and methodological factors act as effect modifiers, influencing disease course, primary end-
points and mortality within studies. Through meta-analysis, we report that functional and anatomical endpoints 
following MI in large animal models vary significantly due to variability in study design (Fig. 1).
Methods
Data from control animals from two previous meta-analyses on large animal MI models were collected7,8. In 
both datasets infarct size as a ratio of the area at risk (IS/AAR), infarct size as a ratio of the left ventricle (IS/LV) 
and left ventricular ejection fraction (EF) were extracted and added in the current data if not present. Results 
on peri- and post-procedural mortality were extracted for all studies; peri-procedural meaning within the time-
frame of the infarct-induction process (‘death during surgical procedures’) and post-procedural meaning after 
the disease-inducing procedure. Any procedural complications not due to the induction of the MI itself were 
not counted as ‘natural’ mortality. Due to evolving methodology over time in MI modeling with regards to the 
treatment of ventricular fibrillation (VF) during induction of MI, we recorded whether animals were treated for 
VF (either by medication or defibrillation) or were excluded immediately and performed a predefined sensitivity 
analysis to exclude a potential effect of this specific early exclusion. A thorough explanation of methodology on 
mortality data extraction can be found in the Supplementary section.
Pre-defined variables of interest were species, sex, age, weight, use of immunosuppression, co-medication 
commonly used in clinical care of MI (defined as being treated for the whole study after MI with one or more of 
the following compounds: aspirin, clopidogrel, ticagrelor, prasugrel, beta-blockers, ACE-inhibitors, angiotensin 
receptor blockers, and/or statins), follow-up duration post-MI, study quality and multiple characteristics of the 
infarct induction procedure: open-thorax vs closed percutaneous procedure, permanent vs temporary occlusion, 
ischemia duration (if transient occlusion) and type of vessel occluded (left coronary artery (LCA) vs left circum-
flex artery (LCX) vs left anterior descending (LAD) vs right coronary artery (RCA)). The variable method of 
quantification (for infarct size measurement or ejection fraction) was added in the phase of revisions to correct 
for any effect of these methods on regular outcomes. Study quality was assessed using the ‘Collaborative Approach 
to Meta Analysis and Review of Animal Data from Experimental Studies’ (CAMARADES) quality checklist13. As 
data on age and weight was scarcely available in the included studies, we conducted a post-hoc sensitivity analysis 
between minipigs and regular pigs within our species variable, as these substantially differ with regards to total 
body weight and age. All studies that did not report the strain of pigs were pooled in an ‘unreported’ variable.
Any variable not already assessed prior to this project, was added to the database.
All data has been inserted in the CAMARADES database (available on request)14.
Statistical analysis. Random effects meta-analysis with restricted maximum likelihood was performed due 
to anticipated heterogeneity between the different models of disease. Forest plots were generated to visualize 
these. Correlation analysis was performed between IS/AAR and EF using linear regression. Correlation between 
the actual therapeutic effect of included studies and the values of control animals was also assessed using linear 
regression.
Univariable meta-regression was performed for the association of chosen variables with our outcomes of 
interest. All variables were subsequently tested in multivariable meta-regression with the outcomes IS/AAR, 
IS/LV, EF and mortality, to correct for potential effect modification and to distinguish independent effects. Of 
note, multivariable meta-regression is especially suitable in the setting of animal studies, as all variables of inter-
est are deliberately kept constant in preclinical study setup as opposed to the clinical setting. This minimalizes 
the risk of a potential ecological bias in our analysis. A post-hoc Wald test was used for categorical univariable 
meta-regression with more than two categories and in multivariable meta-regression to determine the individual 
association per individual variable. We used raw means for the outcomes IS/AAR, IS/LV and EF, since percent-
ages are not expected to differ between the different groups under study.
For mortality outcomes, we used ratios (number of dead animals per total animals) and weighed each meas-
urement on the inversed square root of the total number of animals for each comparison in our meta-regression 
analysis (1/√n). In the case of two measurements in the same procedural setting (for example mentioning of 
mortality peri-procedural both before and after randomization), the appropriate ratio was determined by mul-
tiplying both proportions (1 − ptotal = (1 − p1) * (1 − p2)). The weighing factor for such a value is the square root 
of the total number of animals in both measurements, divided by two (1/√((n1 + n2)/2)). A p-value of <0.05 was 
considered significant.
For our prediction modeling strategy, we used multivariable meta-regression to predict the outcomes for 
commonly used large animal models. We modeled both a pig and a dog model of temporary 60-minute occlusion 
with follow-up of 1 day, 1 week and 1 month. We did the same for a chronic occlusion pig model, using the same 
follow-up times. Statistical analyses were performed using R version 3.1.215 with the additional metafor package16 
and Stata version 11 (Statacorp, LP, Texas, USA). The R script is available in the Supplementary section.
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Results
A total of 246 studies were used, yielding 1500, 1221 and 775 animals for the outcomes IS/AAR, IS/LV and 
EF, respectively (Table 1). For the mortality analyses, data of 3622 animals and 1555 animals was studied for 
peri-procedural and post-procedural mortality, respectively (Table 1).
Meta-analysis. From our datasets, an average IS/AAR of 49.8% (95%CI 46.0–53.6%), IS/LV of 18.1% (95%CI 
16.5–19.7%) and EF of 39.3% (95%CI 37.4–41.2%) were observed after MI induction and follow-up (Table 1). 
These outcomes are also visualized in Forest Plots (Supplementary Figures 1–3). The average peri-procedural 
Figure 1. Graphical schematic representation of differences in outcomes after MI through study design - A 
model using male pigs in combination with an LAD-occlusion will differ significantly from a female dog model 
with LCX-occlusion.
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mortality and post-procedural mortality were 16.7% (95% CI 14.7–18.7%) and 5.2% (95% CI 3.6–6.9%) respec-
tively (Table 1).
Correlation between assessed outcomes. To study the effect of the initial damage and therapeutic effect 
of any drug given, we used linear regression to compare the absolute therapeutic effect within a study and the 
mean outcome that was assessed in the control animals. For IS/AAR (p = 0.0001), IS/LV (p = 0.001) and EF 
(p = 0.05) there was a significant correlation between the effect of the study therapeutic and the initial damage 
in the control animal (Supplementary Figure 4A–C). This indicates that greater cardiac damage leads to a larger 
effect of the investigated therapeutic.
There was no correlation observed between IS/AAR and EF if measured in the same study (p = 0.66, 
Supplementary Figure 5).
Meta-regression on standard outcomes: IS/AAR. Univariable meta-regression revealed multiple cor-
relating variables with all our outcomes (Tables 2–4), which were subsequently used for multivariable analyses.
Multivariable meta-regression (p < 0.001) for the outcome IS/AAR revealed that infarct size was smaller when 
dogs were used (−22% compared to pigs (p < 0.001)). Male animals were also at risk for larger infarcts (−6% 
for both sexes compared to male (p = 0.040) and −10% for unreported sexes compared to male (p = 0.010)). 
The use of co-medication was protective (−18% if used (p = 0.01)) and infarct size was also dependent on the 
type of occlusion (−36% if temporary compared to permanent occlusion (p < 0.001) and −46% if temporary 
compared to unknown occlusion (p < 0.001)). Occlusion of the LAD leads to larger IS/AAR (+8% compared to 
LCX (p = 0.008)) and follow-up duration (−0.3% per hour of follow-up (p = 0.011)) also independently influ-
enced the outcome (Table 2). For all temporary occlusion studies (n = 145), ischemia duration was an additional 
significant influencing variable in multivariable meta-regression of IS/AAR (+0.09%/min ischemia (p = 0.001)) 
(Table 2).
Meta-regression on standard outcomes: IS/LV. Multivariable meta-regression analysis (p < 0.001) 
for IS/LV showed that occluded vessel (p = 0.030) and method of quantification (p = 0.01) are of significant 
influence. For quantification methodology, MRI and planimetry underestimated infarct size compared to tissue 
staining and other modalities. Furthermore, study quality was associated with a 1.3% difference in IS/LV per 
quality point (Table 3). The variables species and sex showed only a trend (p = 0.05 and p = 0.08 respectively) for 
an association, with the same directions for categories as in the IS/AAR analyses (Table 3).
Meta-regression on standard outcomes: EF. Multivariable meta-regression for EF showed an effect of 
species, with a 9% difference in EF for pigs compared to sheep (p = 0.007). Sex also independently influenced 
EF after MI (−6% for female animals compared to male animals (p = 0.03), −7% for female animals compared 
to studies using both sexes (p = 0.028) and −6% for female animals compared to animals with unreported sex 
(p = 0.009)) (Table 4). The choice of occluded vessel also showed an independent effect (+24.2 for only an LAD 
occlusion (p = 0.014), +26.2 for only an LCX occlusion (p = 0.009) compared to a combined LAD/LCX occlu-
sion); again, this should be interpreted with caution, as the number of comparisons using either the LAD or LCX 
in the same study is limited (Table 4). Method of quantification had an independent effect on ejection frac-
tion outcome, with echocardiography estimating higher ejection fraction values compared to LV Angio (+6.7%, 
p = 0.030), SPECT (+7.7%, p = 0.034) and PV loop (+12.6%, p = 0.006).
Mortality. Univariable meta-regression showed no variables investigated correlated with peri-procedural 
mortality (Table 5). The subsequent multivariable meta-regression was non-significant (p = 0.33), so we did not 
proceed with further post-hoc testing. A sensitivity analysis, which omitted all animals that were excluded for VF 
with no attempt to treat the arrhythmia, was performed and also did not show any correlation with the variables 
of interest, both uni- and multivariably.
Univariable meta-regression for post-procedural mortality showed a correlation with follow-up time, with 
the addition of 0.002% per hour extra follow-up (p = 0.03). Multivariably, meta-regression was not significant 
and no further post-hoc analyses were done (p = 0.41). The selected multivariable regression with the addition of 
ischemia duration (which only applies to temporary occlusion models) was significant (p = 0.047) and post-hoc 
testing revealed follow-up time as the only significant independent predictor of post-procedural mortality 
(0.007%/hour, p = 0.001) in studies using a temporary occlusion model.
Datasets
Jansen of Lorkeers 
et al.7
van Hout 
et al.8
This meta-
analysis
Average 
outcome (MA)
IS/AAR 0 1500 1500 49.8%
IS/LV 261 960 1221 18.1%
Ejection Fraction 584 191 775 39.3%
Peri-procedural mortality 1183 2439 3622 16.7%
Post-procedural mortality 365 1190 1555 5.2%
Table 1. Number of included animals per dataset. MA = meta-analysis.
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Univariable Analysis Multivariable analysis
Variable categories n
mean 
(95%CI) p-value post-hoc p-value Variable p-value beta
post-hoc 
p-value
Species
Dog 122 46.4 (43.1–49.7)
<0.001
0.001 (pig vs dog)
Species <0.001
+21.6 if pig (vs 
dog) <0.001
Pig 41 59.3 (53.6–65.0) 0.552 (pig vs sheep)
+1.8 if pig (vs 
sheep) 0.874
Sheep 2 67.5 (41.0–93.9) 0.120 (dog vs sheep)
−19.8 if dog (vs 
sheep) 0.071
Sex
Male 45 47.7 (41.9–53.4)
0.80 All comparisons NS Sex 0.07
+10.5 if male (vs 
female) 0.114
Female 11 50.0 (38.4–61.6)
+10.4 if male (vs 
unknown) 0.010
Both 78 51.3 (46.9–55.6)
−0.1 if female (vs 
unknown) 0.990
Unknown 31 49.5 (42.6–56.4)
+6.3 if male (vs 
both) 0.040
−4.1 if female (vs 
both) 0.491
+4.0 if both (vs 
unknown) 0.255
Immunosupp not applicable Immunosupp not applicable
Comedication
yes 7 43.6 (29.2–58.0)
0.379 Comedication 0.01 −18.2 if used
no 158 50.2 (47.1–53.2)
Open vs closed model
Open 129 50.3 (46.9–53.7)
0.536
0.293 (open vs 
closed)
Open vs closed model 0.22
+4.9 if open (vs 
closed) 0.130
Closed 35 46.7 (40.2–53.3)
0.745 (open vs 
unknown)
−13.1 if open (vs 
unknown) 0.433
Unknown 1 57.0 (18.7–95.3)
0.603 (closed vs 
unknown)
−17.9 if closed (vs 
unknown) 0.287
Occlusion
Permanent 17 69.1 (60.5–77.7)
<0.001
<0.001 
(permanent vs 
temporary)
Occlusion <0.001
+36.3 if permanent 
(vs temporary) <0.001
Temporary 145 47.2 (44.2–50.2)
0.072 (permanent 
vs unknown)
−9.2 if permament 
(vs unknown) 0.343
not known 3 65.9 (45.8–86.0)
0.774 (temporary vs 
unknown)
−45.7 if temporary 
(vs unknown) <0.001
Occluded vessel
LAD 108 54.3 (50.8–57.7)
<0.001
<0.001 (LAD vs 
LCX)
Occluded vessel 0.03
+7.6 if LAD (vs 
LCX) 0.008
LCX 53 40.6 (35.6–45.6)
0.921 (LAD vs 
LAD/LCX)
+2.2 if LAD (vs 
LAD/LCX) 0.788
LAD/LCX 4 55.2 (36.9–73.5)
0.13 (LCX vs LAD/
LCX)
−5.4 if LCX (vs 
LAD/LCX) 0.523
Quantification method
TTC 140 49.1 (45.8–52.3) 0.30 All comparisons NS Quantification method 0.17 All comparisons NS
Nitro blue 10 60.6 (48.7–72.5)
Planimetry 11 48.6 (37.2–60.0)
Other§ 4 54.1 (35.2–72.9)
Follow-up duration 165 −0.02/hour (−0.05–0.01) 0.12 Follow-up duration 0.011 −0.03/hour
Study Quality 165 +0.36/point (−1.7–2.4) 0.734 Study quality 0.945 +0.07/point
Ischemia time 145 −0.01/min (−0.07–0.05) 0.723 Ischemia time*(n = 56) 0.001 +0.09/min
Weight 159 +0.48/kg (0.219–0.743) <0.001 Weight*(n = 159) 0.124 +0.25/kg
Age 5 −0.25/wk (−3.24–2.74) 0.806 Age*(n = 5) not applicable
Table 2. Univariable and multivariable meta-regression for outcome IS/AAR. §MRI, Fluoroluminescence, 
NADH Fluorescence or 111ln-Antimyosin. NS = non-significant. *Variable was added to the multivariable 
model separately, due to missing data. Total multivariable meta-regression was significant (p < 0.0001). n = the 
number of comparisons (=165 in total).
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Post-hoc sensitivity analyses for different pig strains. In a post-hoc analysis we compared the strains 
‘regular pigs’, ‘minipigs’ and ‘unknown strains’ within the species group of pigs. For IS/AAR, univariable metar-
egression was significant (p = 0.025), due to a difference between the unknown group and regular pigs (+13.2% 
if unknown, p = 0.018) and the unknown group and minipigs (+25.7 if unknown, p = 0.048). There was no 
univariable difference for pigs vs minipigs (p = 0.32). These significant differences disappeared in multivariable 
meta-regression (p = 0.15 for the strain variable) (n = 2, 24 and 15 respectively for studies using minipigs, pigs 
and unknown strains). For the outcomes IS/LV (n = 14, 24 and 14) and ejection fraction (n = 28, 40 and 19) 
there was no significant difference between minipigs, pigs and unknown strains in both univariable (p = 0.84 and 
p = 0.91 respectively) and multivariable (p = 0.17 and p = 0.49 respectively) analysis.
Variable
Univariable Analysis Multivariable analysis
categories n mean (95%CI) p-value post-hoc p-value Variable p-value beta
post-hoc 
p-value
Species
Dog 90 16.7 (14.9–18.5)
0.040
0.015 (pig vs dog)
Species 0.05
+6.3 if pig (vs dog) 0.023
Pig 52 20.4 (18.0–22.8) 0.640 (pig vs sheep) −5.4 if pig (vs sheep) 0.502
Sheep 1 24.4 (7.7–41.1) 0.365 (dog vs sheep) −11.7 if dog (vs sheep) 0.160
Sex
Male 35 19.6 (16.7–22.5)
0.247
All comparisons NS
Sex 0.08
+6.5 if male (vs female) 0.047
Female 18 18.7 (14.6–22.8) +5.4 if male (vs unknown) 0.022
Both 50 16.0 (13.6–18.5) −1.2 if female (vs unknown) 0.650
Unknown 40 18.9 (16.2–21.6) +4.0 if male (vs both) 0.033
−2.6 if female (vs both) 0.402
+1.4 if both (vs unknown) 0.492
Immunosupp
yes 3 12.1 (2.1–22.1)
0.236 Immunosupp 0.23 −5.9 if used
no 140 18.2 (16.7–19.7)
Co-medication
yes 9 15.4 (9.4–21.3)
0.361 Co-medication 0.22 −4.0 if used
no 134 18.2 (16.7–19.7)
Open vs closed model
Open 99 18.7 (16.9–20.4)
0.224 Open vs closed model 0.46 −1.5 if open model
Closed 44 16.7 (14.1–19.4)
Occlusion
Permanent 46 20.2 (17.6–22.7)
0.138
0.047 (permanent vs 
temporary)
Occlusion 0.065
+4.1 if permanent (vs 
temporary) 0.012
Temporary 95 17.0 (15.3–18.8) 0.677 (permanent vs unknown)
+0.5 if permament (vs 
unknown) 0.932
not known 2 17.6 (5.4–29.7) 0.933 (temporary vs unknown)
−3.8 if temporary (vs 
unknown) 0.529
Occluded vessel
LAD 93 19.2 (17.4–20.9)
0.004
0.130 (LAD vs LCX)
Occluded vessel 0.009
+0.3 if LAD (vs LCX) 0.869
LCX 47 16.8 (14.4–19.3) 0.002 (LAD vs LAD/LCX)
+15.5 if LAD (vs LAD/
LCX) 0.002
LAD/LCX 3 3.7 (−5.7–13.1) 0.008 (LCX vs LAD/LCX)
+15.2 if LCX (vs LAD/
LCX) 0.004
Quantification Method
TTC 86 17.8 (16.0–19.7) 0.06 0.007 (MRI vs other)
Quantification Method
0.012 +8.3 if Nitro Blue (vs Planimetry) 0.022
Nitro Blue 8 20.8 (15.1–26.5) 0.008 (Planimetry vs other)
+10.1 if Nitro Blue (vs 
MRI) 0.019
Planimetry 22 16.7 (13.1–20.4) 0.01 (TTC vs other) −9.0 if Planimetry (vs Other) 0.026
MRI 19 16.5 (12.6–20.3) Rest of comparisons NS −10.9 if MRI (vs Other) 0.005
Other§ 7 27.5 (20.4–34.5) Rest of comparisons NS
Follow-up duration 143 +0.001/hour (−0.001–0.002) 0.565 Follow-up duration 0.326 −0.001/hour
Study Quality 143 +1.52/point (0.67–2.37) 0.001 Study quality 0.026 +1.3/point
Ischemia time 95 +0.002/min (−0.002–0.006) 0.414 Ischemia time*(n = 95) 0.131 +0.003/min
Weight 137 −0.006/kg (−0.17–0.16) 0.946 Weight*(n = 137) 0.297 −0.10/kg
Age 11 +0.05/wk (−0.14–0.25) 0.568 Age*(n = 11) not applicable
Table 3. Univariable and multivariable meta-regression for outcome IS/LV. §(SPECT−) CT, NOGA mapping or 
Masson’s Trichrome staining, NS = non-significant. *Variable was added to the multivariable model separately, 
due to missing data Total multivariable meta-regression was significant (p < 0.0001). n = the number of 
comparisons (=143 in total)
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Prediction of outcomes in common large animal MI models. Predicted outcomes for predefined 
commonly used models were generated (Table 6), showing clear differences for all outcomes between these 
models.
Variable
Univariable Analysis Multivariable analysis
categories n mean (95%CI) p-value post-hoc p-value Variable p-value beta
post-hoc 
p-value
Species
Dog 15 36.5 (31.3–41.8)
0.011
0.144 (pig vs dog)
Species 0.01
+4.7 if pig (vs 
dog) 0.151
Pig 87 40.7 (38.6–42.8) 0.005 (pig vs sheep)
+8.6 if pig (vs 
sheep) 0.007
Sheep 11 31.9 (26.1–37.7) 0.238 (dog vs sheep)
+3.9 if dog (vs 
sheep) 0.357
Sex
Male 21 37.9 (33.6–42.2)
0.068
0.398 (male vs 
female)
Sex 0.04
+6.3 if male (vs 
female) 0.033
Female 27 35.4 (31.6–39.3) 0.206 (male vs unknown)
+0.2 if male (vs 
unknown) 0.943
Both 15 39.4 (36.9–47.5) 0.018 (female vs unknown)
−6.1 if female (vs 
unknown) 0.009
Unknown 50 41.2 (38.4–44.0) 0.214 (male vs both)
−0.9 if male (vs 
both) 0.789
0.043 (female vs 
both)
−7.2 if female (vs 
both) 0.028
0.741 (both vs 
unknown)
+1.1 if both (vs 
unknown) 0.702
Immunesupp
yes 6 37.4 (29.1–45.7) 0.658
Immunosupp 0.75
−1.3 if used
no 107 39.3 (37.1–41.5)
Co-medication
yes 11 43.7 (37.6–49.9)
0.135 Co-medication 0.21
+4.0 if used
no 102 38.8 (36.8–40.8)
Open vs closed model
Open 50 39.1 (36.2–42.0)
0.868 Open vs closed model 0.90 −0.3 if open modelClosed 63 39.4 (36.8–42.0)
Occlusion
Permanent 56 36.5 (33.9–39.1) 0.013 0.005 (permanent vs temporary) Occlusion 0.12
−4.2 if permanent 
(vs temporary) 0.064
Temporary 55 41.9 (39.2–44.5) 0.175 (permanent vs unknown)
−8.2 if permanent 
(vs unknown) 0.257
not known 2 46.5 (32.2–60.7) 0.531 (temporary vs unknown)
−4.0 if temporary 
(vs unknown) 0.581
Occluded vessel
LAD 89 41.2 (36.7–45.7)
0.011
0.618 (LAD vs 
LCX) Occluded vessel
0.03
−2.0 if LAD (vs 
LCX) 0.389
LCX 23 41.0 (32.4–49.6) 0.003 (LAD vs LAD/LCX)
+24.2 if LAD (vs 
LAD/LCX) 0.014
LAD/LCX 1 10 (−8.1–28.1) 0.003 (LCX vs LAD/LCX)
26.2 if LCX (vs 
LAD/LCX) 0.009
Quantification Method
Echo 56 41.0 (38.4–43.6) 0.04 0.014 (Echo vs PV loop)
Quantification 
Method 0.01
+6.7 if echo (vs 
LV Angio) 0.030
MRI 27 40.6 (36.8–44.4) 0.022 (MRI vs PV loop)
+7.7 if echo (vs 
SPECT) 0.034
LV Angio 27 36.8 (32.0–41.6) Rest of the comparisons NS
+12.6 if echo (vs 
PV loop) 0.006
SPECT 8 40.0 (26.77–41.2) Rest of the comparisons NS
PV loop 5 29.4 (20.6–38.2)
Follow-up duration 113 −0.0002/hour (0–0.0003) 0.338 Follow-up duration 0.11 −0.0004/hour
Study Quality 113 0.14/point (−1.4–1.7) 0.859 Study quality 0.19 −1.0/point
Ischemia time 55 −0.04/min (−0.1–0.05) 0.416
Ischemia 
time*(n = 55) 0.87 0.016/min
Weight 98 0.06/kg (−0.091–0.231) 0.428 Weight*(n = 98) 0.26 +0.09/kg
Age 24 0.17/wk (−0.116–0.449) 0.234 Age*(n = 24) 0.63 −0.18/wk
Table 4. Univariable and multivariable meta-regression for outcome ejection fraction. NS = non significant. 
*Variable was added to the multivariable model separately, due to missing data. Total multivariable meta-
regression was significant (p = 0.0001). n = the number of comparisons (=113 in total).
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Discussion
The current meta-analysis systematically reveals the effect of methodological choices on primary outcome meas-
urements in large animal MI studies. The identification of the effect of the different experimental setups is of great 
importance, since it will guide adequate expectations of study results and mortality for specific models. It also 
enables more adequate and precise power calculations, which are essential when designing any preclinical study. 
We can now quantify biological differentiating variables for certain effect sizes and more accurately determine 
if these models resemble human disease. We confirmed some known biological variability within these mod-
els, showed effects that can be translated to the human situation and were able to quantify these variations in a 
meta-analytic manner.
The different disease manifestation across species has been demonstrated in the past17, with canine hearts 
forming more collaterals than hearts of other species, which we broke down to a ~20% smaller IS/AAR for dog 
models compared to pig models and lower EF in sheep compared to pigs. Despite the ~20% smaller IS/AAR in 
dogs, EF does not differ between dogs and pigs. Supplemental Figure 5 shows the absence of a correlation between 
IS/AAR and EF in our dataset, which could possibly be explained by confounding factors, including follow-up 
time and occluded vessel. Since infarct size decreases over time18 (Table 6), cardiac remodeling affects ejection 
fraction by progressive dilatation and systolic dysfunction. Moreover, occlusion of the LAD results in a loss of api-
cal contractility, leading to a more severe decrease of ejection fraction compared to LCx occlusion19,20. As data on 
age and weight was scarse, we conducted an extra sensitivity analysis to compare minipigs and pigs, as these are 
considered the same species, but differ substantially in terms of age and weight. In this analysis, we could not find 
a difference between the two, arguing that MI models in both strains behave similar in terms of regular outcomes.
Conserved within evolution, females seem to show smaller infarcts compared to mixed groups and male coun-
terparts, which is in line with the clinical data on sex influence on infarct size, favoring female subjects21–23. Of 
note, using female animals might leave researchers with a smaller therapeutic window in infarct size, potentially 
Univariable Analysis Multivariable analysis
Variable categories
% mortality peri-
proc (n) p-value
% mortality post-
proc (n) p-value post-hoc p-value Variable
p-value 
peri-
proc
p-value 
post-
proc beta
Species
Dog 17.8% (93)
0.26
5.4% (122)
0.95 Species NA NAPig 14.6% (68) 5.1% (41)
Sheep 20.3% (9) 4.5% (2)
Sex
Male 15.2% (63)
0.24
5.3% (39)
0.87 Sex NA NA
Female 13.7% (24) 5.% (25)
Both 19.8% (41) 5.9% (59)
Unknown 18.0% (41) 4.1% (30)
Immunosupp yes 0% (1)
0.23
0% (2)
0.44 Immunosupp NA NA
no 16.8% (169) 5.3% (152)
Co-medication
yes 10.9% (7)
0.27
5.7% (7)
0.90 Co-medication NA NA
no 16.9% (163) 5.2% (147)
Open vs closed 
model
Open 16.1% (118) 5.1% (105)
0.78 Open vs closed model NA NAClosed 18.0% (52) 5.6% (49)
Occlusion
Permanent 17.0% (43)
0.24
6.2% (39)
0.005
perm vs 
temp = 0.361
Occlusion NA NATemporary 16.9% (125) 4.6% (114) perm vs unknown = 0.003
Unknown 0% (2) 34.8% (1) temp vs unknown = 0.002
Occluded vessel
LAD 16.8% (116)
0.72
4.8% (102)
0.72 Occluded vessel NA NA
LCX 15.9% (51) 6.4% (48)
LAD/LCX 26.9% (2) 3.7% (3)
Unknown 22.2% (1) 0% (1)
Study Quality −0.77/point (170) 0.28 −0.024/point (154) 0.96 Study Quality NA NA
Follow-up duration −0.004/hr (166) 0.78 0.0023/hr (152) 0.03
Follow-up 
duration 
(n = 113)*
NA <0.001 0.007/hour
Ischemia time 0.006/min (123) 0.10 −0.002/min (114) 0.52 Ischemia time (n = 113)* NA 0.77 −0.0007/min
Weight −0.1/kg (153) 0.29 −0.06/kg (138) 0.30 Weight(n = 153)* NA NA
Age +0.06/wk (15) 0.79 −0.015/wk (12) 0.92 Age(n = 15)* NA NA
Table 5. Univariable and multivariable meta-regression for peri- and post-procedural mortality. *Variables 
added to the multivariable model separately, due to missing data. Multivariable meta-regression was not 
significant (p = 0.33 and p = 0.42). Multivariable meta-regression with the addition of ischemia time was 
significant for post-procedural mortality (p = 0.04). n = the number of comparisons (=170 and 165 in total).
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explaining the reduced efficacy of anti-inflammatory compounds in female animals8. Interestingly, pump func-
tion seems more decreased in female animals, once again arguing that the different sexes do not respond com-
pletely similar to cardiac damage and subsequent remodeling. In this perspective, it is crucial for translational 
success to include both sexes in future preclinical research, as is also called for by the NIH in preclinical projects24. 
Furthermore, there seem to be fewer studies using (only) female animals in our dataset, potentially explaining 
why not all comparisons to the female group always reached statistical significance.
The observed difference of ~9% in IS/AAR for different occlusion sites (LAD vs LCX) is in line with the 
observed greater loss of regional systolic function for anterior wall ischemia25, but was not observed for the out-
come EF.
The observed reduction of infarct size and EF when increasing follow-up time is interesting both from a 
methodological and biological point of view. Smaller infarct sizes might imply smaller therapeutic windows for 
new interventions, while a larger reduction in EF might account for the inverse reasoning. Biologically this might 
be explained by infarct resorption and subsequent myocardial wall thinning, resulting in a decreased attribu-
tion of the thinned scar to the total myocardial mass18. Other explanations could be possible regeneration and 
post-infarction hypertrophy. Hibernating myocardium is not likely to explain this phenomenon, as function 
should increase after myocardial stunning and hibernation in the early stages of an infarct. Regardless of the 
cause, a longer follow-up could lead to more clinically relevant conclusions and might need more power to show 
any true differences. Incorporation of regular MI co-medication also seems to reduce the IS/AAR, which might 
be crucial for clinically relevant translation to the same poly-pharmaceutical human situation. A limitation of 
this variable is of course bundling of all studies using one or more of these compounds for power-reasons; we are 
not able to pinpoint these effects to one single compound. However, for many of these compounds there is either 
preclinical or even clinical evidence that they can influence infarct size and other outcomes after MI and therefore 
might be relevant to take into account for future experimental study design26,27.
The addition of quantification method seems crucial to be able to correct for the effects that these have on 
our different outcomes. For ejection fraction especially, it is known that echocardiography can overestimate car-
diac function compared to for example MRI28. Our analyses confirm this, making it crucial to correct for these 
methods in multivariable analyses.
Interestingly, the composition of the dataset blurred the effect of multiple variables in the univariable analysis 
for IS/AAR, while our multivariable approach revealed certain effects that would otherwise have gone unnoticed.
No difference in outcome was observed for open versus closed modeling of MI, in contrast to what has 
been demonstrated in a recent study29. This might mean that conclusions from certain experiments can only be 
applied to the same setting; in this case an ischemia-reperfusion pig model. On the other hand, it might imply 
that meta-analyses cannot reveal all subtle differences within MI animal models. The same holds true for other 
variables in our dataset, like immunosuppression, which theoretically could have an effect on all our outcomes 
of interest.
Furthermore, we are limited by the data we were able to extract. In preclinical meta-analyses, many ‘known 
unknowns’ are present; variables that one would like to analyze, but are not reported as such. This is resembled by 
the unexplained heterogeneity (for multivariable IS/AAR analysis R2 = ~46% and I2 = ~96%) that, in the case of 
our MI analyses, is potentially influenced by for example the specific occlusion site of the vessel (which directly 
influences the area at risk), weight of the animal or experience of the surgeon. However, with the variables avail-
able, we were able to explain a significant part of the observed heterogeneity, with model-specific differences and 
human-like variability for sex and co-medication.
Modeling mortality in our study did not result in many explanatory variables, so we can only give summary 
estimates based on the meta-analysis of the total data. On average, peri-procedural mortality was ~17%, while 
post-procedural mortality was condensed in a ~5% mortality rate. These are important numbers for future study 
designs, as power analyses are crucial in the success chance of (pre)clinical trials and the reduction of both type I 
and type II errors. It is possible that these numbers are incomplete or biased in the current analysis, due to incom-
plete reporting in prior studies. This might be less of a problem for future similar analyses as the reporting of 
Infarct size/Area at Risk Infarct size/Left Ventricle Ejection Fraction
Pig I/R (60 min) LAD model
1 day 60% 19% —†
1 week 55% 18% 42%
4 weeks (37%)* 18% 42%
Dog I/R (60 min) LAD model
1 day 40% 15% —†
1 week 35% 15% 36%
4 weeks (18%)* 14% 36%
Pig permanent LAD model
1 day 88% 24% —†
1 week 82% 24% 38%
4 weeks (60%)* 24% 38%
Table 6. Predicted regular outcomes for common large animal MI models. *Assuming linear effect of follow-up 
duration. †Not calculated due to few measurements and myocardial stunning.
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animal studies will hopefully improve substantially due to the ARRIVE guidelines, EDA application and journals 
demanding complete reporting30,31.
The need for meta-research on methods and reproducibility has been solicited for by the community and is 
a crucial process in the self-cleansing ability of research10. This paper untangled a part of the variation observed 
and generates realistic starting points for well-needed large animal MI models, hopefully adding further insight 
in disease understanding, accurate modeling of MI and more translational success for new cardiac interventions.
Being able to explain and predict a ‘point of departure’ in large animal MI models will prove useful to tailor 
experiments and make reasonable power calculations based on the expected damage, mortality and potential 
experimental effect (example in Fig. 1). This will potentially result in more accurately powered studies, more defi-
nite answers to research questions and less waste of animal lives and research money32. Many clinically relevant 
patient characteristics seem to be of influence in the preclinical setting, and will potentially influence any outcome 
if not taken into account. In the current era of translational science, all researchers need to take this variation into 
account when designing new studies to optimize the chance of success of any large animal experiment.
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